Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them ...

Eli Lilly (LLY) stock in focus as the company expands Zepbound offerings with new vial formats at discounted prices. Read ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.